Moderna Beats on Q1 Earnings, Lags on Revenues, Focuses on Cost Cuts

Moderna (MRNA) incurred a loss of $2.52 per share in the first quarter of 2025, narrower than the Zacks Consensus Estimate of a loss of$2.92. In the year-ago period, the company had reported a loss of $3.07.Total revenues in the quarter were$108 million, which missed the Zacks Consensus Estimate of $127 million. Revenues declined around 35% year over year, owing to lower net product sales. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.)More on MRNA’s Q1 EarningsModerna currently ...